1. 413PDPhase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma. (23rd October 2018) Authors: Krebs, M; Lopez, J; El-Khoueiry, A; Bang, Y-J; Postel-Vinay, S; Abidah, W; Im, S-A; Khoja, L T; Standifer, N; Jones, G N; Marco-Casanova, P; Frewer, P; Berges, A; Cheung, A; Stephens, C; Felicetti, B; Dean, E; Pierce, A; Hollingsworth, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. (23rd October 2018) Authors: Javle, M; Kelley, R K; Roychowdhury, S; Weiss, K H; Abou-Alfa, G K; Macarulla, T; Sadeghi, S; Waldschmidt, D; Zhu, A X; Goyal, L; Borad, M; Yong, W P; Borbath, I; El-Khoueiry, A; Philip, P; Moran, S; Ye, Y; Ising, M; Lewis, N; Bekaii-Saab, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗